Panevezio Statybos Lt 1 Stock
€0.56
Your prediction
Financial data and news for PST
sharewise wants to provide you with the best news and tools for PST, so we directly link to the best financial data sources.
Financials
News
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Key Points
- Interested in Bicara Therapeutics Inc.? Here are five stocks we like better.
- Bicara Therapeutics said new ASCO data support ficerafusp alfa in first-line recurrent or metastatic
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell

